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INTRODUCTION
Numerous clinical syndromes have been reported in 
association with hepatitis C virus (HCV) infection. Some 
are well established while others remain a speculation (Table 
1)[1], Fourteen to seventy percent of  patients with HCV 
have detectable cryoglobulins in their serum even in the 
absence of  rash, weakness or arthralgias[1], whereas 50-90% 
of  patients with mixed cryoglobulinaemia are reported to 
have HCV infection[2]. It is suggested that approximately 
10% of  type II mixed cryoglobulinaemiae can evolve into 
malignant lymphoma several years after diagnosis.
Epidemiological studies from Europe, Japan and 
North America also implicate that HCV plays a role in 
the pathogenesis of  non-Hodgkin lymphomas (NHL)[3-7]. 
HCV infection is detectable in a signifi cant proportion of  
NHL (14-52%), nonetheless, it has not been confi rmed[8]. 
A 50-fold elevation in the risk for NHL of  the liver or 
salivary glands has been reported in an Italian case-control 
study, which is greater than the relative risk of  hepatocel-
lular carcinoma. The relative risk for NHL of  other sites is 
increased about 4-fold[9]. An association between multiple 
myeloma (MM) and chronic HCV infection has been sug-
gested by some epidemiological studies[2,9].
CASE REPORT
The authors report a case of  a 50 year-old woman with 
chronic HCV infection who has been followed up since 
1998 due to high viral load (13.47 MEq/mL), genotype 
1b and moderately elevated liver function tests (LFTs). 
The patient received treatment of  chronic backache 
and tonsillectomy prior to admission to our hospital. 
Laboratory data and liver biopsy revealed moderate activity 
(grade 5/18, stage I). In April 1999, one-year interferon 
therapy (3x3ME/wk) was initiated. HCV-RNA became 
negative with normalization of  the LFTs. However, the 
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Abstract
An association between chronic hepatitis C virus (HCV) 
infection and essential mixed cryoglobulinaemia and non-
Hodgkin lymphoma (NHL) has been suggested. However, 
a causative role HCV in these conditions has not been 
established. The authors report a case of a 50 year-old 
woman with chronic hepatitis C (CHC) who has been fol-
lowed up since 1998 due to a high viral load, genotype 
1b and moderately elevated liver function tests (LFTs). 
Laboratory data and liver biopsy revealed moderate ac-
tivity (grade: 5/18, stage: 1/6). In April 1999, one-year 
interferon therapy was started. HCV-RNA became nega-
tive with normalization of LFTs. However, the patient re-
lapsed during treatment. In September 2002, the patient 
was admitted for chronic back pain. A CT examination 
demonstrated degenerative changes. In March 2003, 
multiple myeloma was diagnosed (IgG-kappa, bone 
marrow biopsy: 50% plasma cell infi l). MRI revealed a 
compression fracture of the 5th lumbar vertebral body 
and an abdominal mass in the right lower quadrant, in-
fi ltrating the canalis spinalis. Treatment with vincristine, 
adriamycin and dexamethasone (VAD) was started and 
bisphosponate was administered regularly. In January 
2004, after six cycles of VAD therapy, the multiple my-
eloma regressed. Thalidomide, as a second line treat-
ment of refractory multiple myeloma (MM) was initiated, 
and followed by peginterferon-α2b and ribavirin against 
the HCV infection in June. In June 2005, LFTs returned 
to normal, while HCV-RNA was negative, demonstrating 
an end of treatment response. Although a pathogenic 
role of HCV infection in malignant lymphoproliferative 
disorders has not been established, NHL and possibly 
MM may develop in CHC patients, supporting a role of a 
complex follow-up in these patients.
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PO Box 2345, Beijing 100023, China                                                                                                                     World J Gastroenterol  2006 April 14; 12(14): 2297-2300
www.wjgnet.com                                                                                                                                          World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                       © 2006 The WJG Press. All rights reserved.
patient relapsed in the 7th mo of  treatment (HCV-RNA 
became positive, LFTs increased). The liver function 
tests are summarized in Figure 1. In February 2000, 
hypothyroidism was diagnosed, substitution was initiated 
and follow-up was scheduled. 
In September 2002, the patient was admitted for 
chronic back pain. CT examination revealed degenerative 
changes of  the 5th lumbar vertebral body. Subsequently, the 
patient was not monitored until March 2003, when she was 
again hospitalized due to chronic backache and weakness 
of  the right lower limb. Based on laboratory results, 
IgG-κ multiple myeloma was diagnosed (erythrocyte 
sedimentation rate; ESR): 104 mm/h, IgA: 0.18 g/L, IgG: 
41.86 g/L, IgM: 0.29 g/L and 12.8% M-component on 
serum immunoelectrophoresis; bone marrow biopsy: 50% 
plasma cell infi l). Mixed cryoglobulins were detected in the 
serum. Anemia, low platelet count or hypercalcaemia did 
not occur during follow-up. Serum IgG was elevated from 
1998. However, monoclonality was not detected prior to 
March 2003. The serum immunoglobulin data and ESR 
are presented in Figure 2. MRI revealed a compression 
fracture of  the 5th lumbar vertebral body and an abdominal 
mass in the right lower quadrant, infiltrating the canalis 
spinalis, ileum and sacroiliac joint (osteolytic lesions). 
An aggressive treatment regimen was implemented 
with vincristine, adriamycin and dexamethasone (VAD). 
From April to October 2003, she received six cycles of  
VAD therapy followed by multiple myeloma’s regression. 
The presence of  compression fracture also prompted 
www.wjgnet.com
the regular adminis of  bisphosponate (Aredia). In 
January 2004, 22.2% M-components were detected by 
immunoelectrophoresis, yet the ESR was normal (17mm/
h). Methyl prednisolone (100mg b.i.d) and cytoxane (100mg 
o.d.) p.o. therapy was started.
In April 2004, she was admitted to the Haematological 
Department for paraparesis. Laminectomy (Th VII-IX) 
with myelon decompression and tumor resection was 
performed. Therapy was amended with thalidomide (100mg 
o.d.) orally. In August, repeated CT scans demonstrated 
compression fractures at L5 and S2 accompanying 
narrowing of  the spinal canal at L5. In September, due to 
worsening of  the paraparesis, a second laminectomy was 
performed (L5-S1) followed by insertion of  a stabilizing 
prosthesis (L4-S1).
In June 2004, weekly peginterferon-α2b (1.5μg/kg) and 
800mg ribavirin (daily) were prescribed (HCV PCR 145000 
IU/mL, Roche TaqMan). No further dose adjustment was 
necessary. The LFTs became normal and PCR returned 
negative after three months of  therapy, indicating an early 
viral response (EVR). In June 2005, the LFTs were normal 
with a negative HCV-PCR, demonstrating an end of  
treatment response (ETR).
DISCUSSION
In recent years, major advances have been made in the 
treatment of  HCV infection with the sustained response 
rate of  52-63% achieved[11-13]. A major disadvantage in 
Hungary is that the hard-to-treat genotype 1 is almost 
universal (90-95%) and occurs much more frequently 
compared to that in other European countries[13, 14].
Apart from hepatocellular carcinoma, HCV infection 
is also associated with various extrahepatic diseases, 
including mixed cryoglobulinaemia and NHL. Fourteen 
to seventy percent of  patients with HCV have detectable 
cryoglobulins in their serum[1, 2], while 50-90% of  patients 
with mixed cryoglobulinaemia are reported to have HCV 
infection. 
Epidemiological case-control studies from the 1990s 
suggest that chronic HCV infection is associated with 
the development of  NHL. It was reported that 9 % and 
11.5% of  NHL patients are HCV-antibody positive[15,16]. 
Germanidis et al[4] investigating 201 NHL patients and 
found that the prevalence of  HCV infection is 2-fold 
Table 1 Extrahepatic diseases associated with hepatitis C virus 
infection
  Association: strong Intermediate Weak 
-Cryoglobulinemic syndrome
  (Cutaneous leukocytoclastic 
vasculitis, arthritis, weakness)
      -Porphyria cutanea
       tarda
      -Diabetes 
-Thyroid disease
-Corneal ulcers 
-Lichen planus 
-Pulmonary
  fi brosis 
-Renal disease
 ( m e m b r a n o p r o l i f e r a t i v e
   glomerulo- nephritis)
-Peripheral neuropathy 
-Non-Hodgkin lymphoma 
-Sjörgen’s syndrome
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Figure 1 Liver function tests from April 1998 to July 2005.
Figure 2 ESR and serum immunoglobulin levels from April 1998 to July 2005.
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higher than that in controls[4]. More recent studies have 
further confi rmed this fi nding. A Japanese study showed 
that 17% of  patients with B-cell NHL are HCV-antibody 
positive compared to 6.6% of  controls[6]. Moreover, an 
East European study[7] reported that 6 out of  42 (24.3%) 
NHL patients are HCV-antibody positive. In contrast, 
Rabkin et al[8] investigated the stored sera of  57 NHL 
patients, 24 MM patients and fourteen Hodgkin’s disease 
patients, and found that only four patients are HCV-
antibody positive.
An association between chronic HCV infection and 
MM is also found in epidemiological studies. Gharagozloo 
et al[2] showed that HCV antigens are detectable in 11% of  
patients with MM, 69% of  patients with essential mixed 
cryoglobulinaemia and 4.3% of  patients with NHL, using 
recombinant immunoblot assay (RIBA) and enzyme-linked 
immunosorbent assay (ELISA). Another study revealed 
that HCV infection is found in 32% of  MM patients[10]. 
The former is associated with 4.3-fold risk for MM. 
The possible mechanism by which HCV infection 
leads to stimulation of  B cells is starting to unravel. It is 
well documented that HCV infection, as observed in our 
case, usually precedes NHL by many years[9]. Hepatitis 
C is lymphotropic and may replicate in lymphocytes and 
hepatocytes[17]. The second portion of  the HCV enve-
lope (E2 protein) binds to CD81[18], suggesting that this 
phenomenon is associated with CD19 and CR2 as well as 
MHC class II molecules on lymphocytes. The binding of  
CD81 to B cells can activate this complex, which lowers 
the antigen threshold necessary for antibody stimulation, 
thus rendering the B cell hyper-responsive. Sequencing of  
the antigen-binding region of  immunoglobulin produced 
by malignant lymphocytes demonstrates that it has a high 
degree of  homology to both antibodies specific for E2, 
as well as the antibodies produced by B cells that secrete 
RF. Furthermore, 88% of  patients with HCV infection 
and cryoglobulinaemia demonstrate over-expression 
[t(14,18)translocation] of  the anti-apoptotic bcl-2 gene, 
compared with 8% of  patients with HCV infection, 2% 
of  patients with other liver diseases, and 3% of  individuals 
with other rheumatoid disorders, which cause enhanced 
B cell survival[19]. In addition, over-expression of  NF-kB 
has been reported in lymphocytes and liver samples of  pa-
tients with chronic HCV infection and those with NHL[20, 
21]. This is an important fi nding, as NF-kB plays a key role 
in virus-induced lymphomagenesis. Mutations of  the NF-
kB gene are common in lymphoid malignancies[22] and 
alterations of  NF-kB could initiate changes in downstream 
regulatory pathways. A second mutation (e.g. myc, NF-kB) 
could possibly initiate the progression to lymphoma[23]. 
In conclusion, although a pathogenic role of  HCV 
infection in malignant lymphoproliferative disorders has 
not been established, NHL and possibly MM may develop 
in cases of  CHC, supporting the need for a complex 
follow-up in these patients.
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